Clinical trials
CTD-ILD clinical trials
Below are recruiting ctd-ild clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT05819385Recruiting
Study of lung scarring in immune diseases
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
Mexico CityAges 18 years+ - NCT06574581RecruitingPhase 1/Phase 2
Adipose stem cells for connective tissue disease with lung scarring
This trial tests whether stem cells from fat tissue can help people with connective tissue diseases (like lupus or scleroderma) whose lung scarring has worsened despite standard treatments. It aims to slow or stop lung damage.
TaichungAges 20–80 - NCT06576271RecruitingPhase 1
Testing a new drug for lupus and related lung disease
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
Scottsdale, ArizonaAges 18–65 - NCT06674148RecruitingPhase 2/Phase 3
Qifangfeixian granules for connective tissue disease lung scarring
This trial tests a Chinese herbal medicine called Qifangfeixian granules for people with lung scarring (interstitial lung disease) related to connective tissue diseases (like lupus or scleroderma). It compares the medicine to a placebo to see if it helps improve breathing and lung function.
Wuhan, HubeiAges 18–80 - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new CTD-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ctd-ild?
- Yes. Clin2 currently lists 6 recruiting ctd-ild studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ctd-ild trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ctd-ild trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.